Literature DB >> 819438

Purification and binding properties of human platelet factor four.

R I Handin, H J Cohen.   

Abstract

Methods are described for the purification of a heparin-neutralizing protein from human platelets. The protein, obtained by conventional or affinity chromatographic techniques, is homogeneous by disc and sodium dodecyl sulfate gel electrophoresis, immunoelectrophoresis, and gel electrofocusing and can be obtained in a final yield of 75%. The protein has a subunit molecular weight of 9600, an isoelectric point at pH 7.6, and 18% basic and 22% acidic amino acid residues. The purified heparin-neutralizing protein forms dissociable complexes with heparin as measured by electrophoretic and Millipore filtration techniques employing [3H]heparin. The ability of a series of sulfated glycosaminoglycans to displace [3H]heparin from the binding protein was compared. The mole ratios required were: heparin less than heparan sulfate less than dermatan sulfate less than chondroitin 6-sulfate less than chondroitin 4-sulfate. Although the degree of sulfation of the aminoglycans correlated with the ability to displace [3H]heparin, the conformation fo the carboxyl group of the uronic acid and the location of the sulfate groups on the amino sugar also influenced the affinity for the protein. Evidence is also presented that binding to aminoglycans occurs via ionic interactions between lysine residues on the protein and negatively charged groups on the aminoglycan. Chemical modification of lysines by guanidination decreased heparin-neutralizing and binding activity, while modification of arginine residues had no effect. Heparin could prevent lysine modification when specifically bound to the heparin-neutralizing protein, but did not prevent lysine modification of other proteins.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 819438

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia.

Authors:  Lubica Rauova; Jessica D Hirsch; Teshell K Greene; Li Zhai; Vincent M Hayes; M Anna Kowalska; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2010-08-19       Impact factor: 22.113

2.  Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.

Authors:  Lubica Rauova; Li Zhai; M Anna Kowalska; Gowthami M Arepally; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

Review 3.  Fundamental concepts in the pathobiology of heparin-induced thrombocytopenia.

Authors:  J L Januzzi; I K Jang
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

4.  Regulation of human mast cell tryptase. Effects of enzyme concentration, ionic strength and the structure and negative charge density of polysaccharides.

Authors:  S C Alter; D D Metcalfe; T R Bradford; L B Schwartz
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

5.  Binding of heparin to human platelet factor 4.

Authors:  S W Cowan; E N Bakshi; K J Machin; N W Isaacs
Journal:  Biochem J       Date:  1986-03-01       Impact factor: 3.857

6.  Low-molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q.

Authors:  S Uwatoko; M Mannik
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

7.  Leukocyte integrin Mac-1 (CD11b/CD18, αMβ2, CR3) acts as a functional receptor for platelet factor 4.

Authors:  Valeryi K Lishko; Valentin P Yakubenko; Tatiana P Ugarova; Nataly P Podolnikova
Journal:  J Biol Chem       Date:  2018-03-14       Impact factor: 5.157

8.  Identification and characterization of PF4varl, a human gene variant of platelet factor 4.

Authors:  C J Green; R S Charles; B F Edwards; P H Johnson
Journal:  Mol Cell Biol       Date:  1989-04       Impact factor: 4.272

9.  Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications.

Authors:  Michele P Lambert; Lubica Rauova; Matthew Bailey; Martha C Sola-Visner; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

10.  Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.

Authors:  D A Lane; J Denton; A M Flynn; L Thunberg; U Lindahl
Journal:  Biochem J       Date:  1984-03-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.